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Abstract
 
The study of hepatitis C virus (HCV), a major cause of chronic liver disease, has been ham-
pered by the lack of a cell culture system supporting its replication. Here, we have successfully
generated infectious pseudo-particles that were assembled by displaying unmodified and func-
tional HCV glycoproteins onto retroviral and lentiviral core particles. The presence of a green
fluorescent protein marker gene packaged within these HCV pseudo-particles allowed reliable
and fast determination of infectivity mediated by the HCV glycoproteins. Primary hepatocytes
as well as hepato-carcinoma cells were found to be the major targets of infection in vitro
 
.
 
 High
infectivity of the pseudo-particles required both E1 and E2 HCV glycoproteins, and was neu-
tralized by sera from HCV-infected patients and by some anti-E2 monoclonal antibodies. In
addition, these pseudo-particles allowed investigation of the role of putative HCV receptors.
Although our results tend to confirm their involvement, they provide evidence that neither
LDLr nor CD81 is sufficient to mediate HCV cell entry. Altogether, these studies indicate that
these pseudo-particles may mimic the early infection steps of parental HCV and will be suitable
for the development of much needed new antiviral therapies.
Key words: hepatitis • viral assembly • glycoproteins • receptor • neutralization
 
Introduction
 
Worldwide, several hundred million people are infected
with the hepatitis C virus (HCV;
 
*
 
 reference 1). Progression
to chronic disease occurs in the majority of HCV-infected
persons. Infection is associated with an increased risk for
liver disease and hepato-cellular carcinoma and has become
the main indication for liver transplantation. HCV infec-
tion also increases the number of complications in HIV-
infected people (2). No vaccine is currently available to
prevent new infections and the only treatment for chronic
hepatitis C is interferon-
 

 
 therapy, either alone or in com-
bination with the guanosine analogue ribavirin. However,
only 
 

 
40% of patients respond to treatment. Clearly, novel
therapeutic strategies are urgently required as the health
costs for HCV-infected people are predicted to spiral dra-
matically in the next few decades.
Unfortunately, no efficient and reliable culture system is
available to amplify the virus (3), preventing the elabora-
tion of reliable infection assays. Recently, a model for
HCV replication, based on the self-replication of engi-
neered minigenomes in cell cultures, has been established
(4, 5). Although very useful in the study of HCV genomic
replication, this system does not support production of
HCV particles (6). HCV virus-like particles have been gen-
erated in insect cells or, alternatively, by pseudotyping ve-
siculovirus or influenza virus particles with modified HCV
E1 and E2 glycoproteins, harboring alterations in their
transmembrane domains (7–10). However, they were only
poorly infectious or not at all, and inconsistencies in the re-
sults prevented their use in functional investigations of
HCV cell entry (7, 8). Therefore, new approaches are
sorely needed to study HCV assembly and infection to de-
sign HCV cell entry inhibitors and to study the humoral
immune response against HCV. Here, we sought to over-
come these hurdles by developing infectious, genetically
tagged HCV pseudo-particles harboring unmodified E1
and E2 glycoproteins. High infectivity of these particles
allowed the precise investigation of HCV E1 and E2 glyco-
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Abbreviations used in this paper:
 
 GFP, green fluorescent protein; HCV, hep-
atitis C virus; HCVpp, HCV pseudo-particles; LDLr, low density lipoprotein
receptor; MLV, murine leukemia virus; PBMC, peripheral blood mononu-
clear cell; TU, transducing unit; VLDL, very low density lipoprotein.
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proteins and their potential receptors in cell entry, HCV
host-range, and neutralization by antibodies from HCV
patient sera.
 
Materials and Methods
 
HCV E1E2 Expression Constructs. 
 
The phCMV-7a expres-
sion vector (see Fig. 1 A) encoding the E1 and E2 glycoproteins
from a 1a-type HCV was generated by inserting into a nonpack-
ageable, CMV promoter-driven expression construct (see Fig. 1
B; reference 11) a DNA fragment encoding the last 60 residues of
HCV core and all of the E1 and E2 proteins that were iso-
lated from pSKp5E1E2, a construct derived from the
pTM1p5E1E2(745) plasmid (12). The phCMV-E1 expression
vector (see Fig. 1 A), expressing only HCV E1 glycoprotein, was
derived from phCMV-7a by adding a stop codon to the COOH
terminus of E1 with primers 5
 

 
-actggacgacgcaaagctgc-3
 

 
 and 5
 

 
-
cgcggatcctacgcgtcgacgccggcaaa-3
 

 
. The resulting PCR fragment
was digested with BamHI and ligated into BamHI-digested ph-
CMV-7a. The phCMV-E2 construct (Fig. 1 A), only expressing
an HCV E2 glycoprotein, was obtained by fusing the NH
 
2
 
 termi-
nus of E2 to the COOH terminus of the HCV core using two
PCR fragments generated with the two primer pairs 5
 

 
-tgcccgct-
tcagccgaaacccacgtcaccggggga-3
 

 
 
 

 
 5
 

 
-gccagaagtcagatgctcaagg-3
 

 
and 5
 

 
-tactctgagtccaaaccg-3
 

 
 
 

 
 5
 

 
-gtgacgtgggtttcggctgaagcgggca-
cagtcag-3
 

 
. The two PCR fragments were fused in a second-
round PCR. The resulting DNA fragment was digested with
BamHI and ligated into BamHI-cut phCMV-7a. Expression vec-
tors for E1E2 glycoproteins of 1b genotype were constructed by
similar strategies.
 
Packaging and Transfer Vectors Constructs. 
 
The CMV-Gag-Pol
murine leukemia virus (MLV) packaging construct, encoding the
MLV 
 
gag
 
 and 
 
pol
 
 genes, and the MLV-GFP plasmid, encoding an
MLV-based transfer vector containing a CMV-GFP internal
transcriptional unit, were described previously (see Fig. 1 B; ref-
erence 11). The pCMV
 

 
8.2 (13) HIV-1 Gag-Pol packaging con-
struct contains all HIV-1 genes except 
 
env
 
, which encodes the
envelope glycoproteins, and 
 
nef
 
. The HPPT-EF1
 

 
-GFP (14)
HIV-1–based transfer vector contains the EF1
 

 
 internal pro-
moter driving the eGFP marker gene. The gene encoding GFP
in this latter vector was replaced by the nlslacZ gene, encoding a
nuclear-targeted 
 

 
-galactosidase, to obtain the HPPT-EF1
 

 
-
nlslacZ HIV-1–based vector. The phCMV-G (11) and phCMV-
RD (15) expression vectors encode the vesicular stomatitis virus
(VSV) G protein and the feline endogenous virus RD114 glyco-
proteins, respectively.
 
Cells. 
 
The following cells were grown as recommended by
the American Type Culture Collection: 293T human embryo
kidney cells (CRL-1573); Huh-7 human hepatocellular carci-
noma (16); PLC/PRF/5 human hepatoma (CRL-8024); Hep 3B
human hepatocellular carcinoma (HB-8064); HepG2 human
hepatocellular carcinoma (HB-8065); A431 human epidermoid
carcinoma (CRL-1555); Caco-2 human colon adenocarcinoma
(HTB-37); HCT 116 human colorectal carcinoma (CCL-247);
HOS human osteosarcoma (CRL-1543); HT-1080 human fibro-
sarcoma (CCL-121); HT-29 human colorectal adenocarcinoma
(HTB-38); LoVo human colorectal adenocarcinoma (CCL-229);
MCF-7 human breast adenocarcinoma (HTB-22); TE671 human
rhabdomyosarcoma (CRL-8805); U118 human glioblastoma
(HTB-15); Jurkat human T cell leukemia (TIB-152); CEM hu-
man lymphoblastic leukemia (CCL-119); Molt-4 human lym-
phoblastic leukemia (CRL-1582); Raji Burkitt’s lymphoma
(CCL-86); CMMT Rhesus monkey mammalian carcinoma
(CRL-6299); COS-7 African green monkey fibroblasts kidney
(CRL-1651); Vero African green monkey kidney (CCL-81);
PG-4 feline astrocyte (CRL-2032); BHK-21 golden hamster kid-
ney (CCL-10); Chinese hamster ovary (CCL-61); BRL 3A rat
hepatocytes (CRL-1442); NIH/3T3 mouse fibroblasts (CRL-
1658); and QT6 quail fibrosarcoma (CRL-1708). 
Cryopreserved primary hepatocytes, isolated from human
adult biopsy samples checked for absence of HBV, HCV, and
HIV, were purchased from Biopredic International and cultured
on collagen I–coated plates according to recommendations of the
supplier. Peripheral blood mononuclear cells (PBMCs), derived
from healthy blood donors, were isolated, cultivated, and infected
as described previously (14, 15).
 
Production and Detection of Pseudo-particles. 
 
To generate HCV
pseudo-particles, 293T cells were transfected with expression
vectors encoding the viral components (see Fig. 1 B), i.e., E1E2
glycoproteins, retroviral core proteins, and packaging-competent
GFP- or nlslacZ-containing retroviral transfer vectors. In brief,
the Gag-Pol packaging construct (8.1 µg), the transfer vector
construct (8.1 µg), and the glycoprotein-expressing construct (2.7
µg) DNAs were transfected into 2.5 
 

 
 10
 
6
 
 293T cells seeded the
day before in 10-cm plates using a calcium phosphate transfection
protocol (CLONTECH Laboratories, Inc.), as described previ-
ously (11). The medium (8 ml/plate) was replaced 16 h after
transfection. Supernatants containing the pseudo-particles were
harvested 24 h later, filtered through 0.45-µm pore-sized mem-
branes, and used in infection assays. Purified virus samples were
obtained by ultracentrifugation of 10-ml viral supernatants
through a 1.5-ml 20% sucrose cushion in an SW 41 Beckman ro-
tor (25,000 rpm, 2.5 h, 4
 

 
C). Viral pellets were suspended in 50
µl PBS. Immunoblots of producer cell lysates and purified
pseudo-particles were performed as described previously (15).
Fractionation of the sucrose cushion purified viral pellets was
achieved by an overnight equilibrium density centrifugation in a
20–60% sucrose gradient at 35,000 rpm and 4
 

 
C in a Beckman
SW 41 rotor. Fractions of 0.7 ml were collected, precipitated
with TCA, and analyzed by Western blotting.
 
Infection Assays. 
 
Target cells were seeded in 12-well plates at
a density of 8 
 

 
 10
 
4
 
 cells per well and incubated overnight at
37
 

 
C. Unless otherwise indicated, dilutions of viral supernatants
containing the pseudo-particles were added to the cells and the
plates were incubated for 3 h. The supernatants were removed and
the cells were incubated in regular medium for 72 h at 37
 

 
C. The
infectious titers, expressed as transducing units (TU) per milliliter,
were deduced from the transduction efficiencies, determined as
the percentage of GFP-positive cells measured by FACS
 
®
 
 analysis
(15). Transduction efficiency of hepatocytes was determined by
counting GFP-positive cells under a UV microscope.
 
Results
 
HCV Pseudo-particles Can Be Assembled In Vitro. 
 
HCV
proteins are expressed from a single polyprotein precursor
and individually released in their respective cell compart-
ments on cleavage by cellular and viral proteases (3, 17).
The envelope of HCV is thought to consist of two glyco-
proteins, E1 and E2, which reside in the ER, where they
associate as heterodimers in their prebudding form (18, 19).
Therefore, HCV E1E2 glycoproteins were expressed from
a polyprotein containing the COOH terminus of the core
(Fig. 1 A, C) protein, which serves as signal peptide for E1,
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and the E1 and E2 glycoproteins (Fig. 1 A; reference 18).
This 
 

 
CE1E2 polyprotein was expressed by transient trans-
fection in 293T cells by using an expression construct un-
der control of the CMV immediate-early promoter (Fig. 1
B). As shown by FACS
 
®
 
 analysis (see Fig. 2 A) and in situ
immunofluorescence (unpublished data) of permeabilized
or nonpermeabilized transfected cells, the E1 and E2 glyco-
proteins were strongly expressed in the cell cytoplasm but
could also be detected at the cell surface.
HCV pseudo-particles (HCVpp) were generated by as-
sembling these full-length, unmodified E1 and E2 glyco-
proteins onto retroviral core proteins derived from MLV.
Such pseudo-particles were obtained with E1E2 glycopro-
teins, derived from HCV genotypes 1a and 1b, that stand
among the most prevalent and most resistant to interferon-
 

 
therapy (20). Retroviruses were chosen as platforms for
assembly of HCVpp because their cores can incorporate a
variety of different cellular and viral glycoproteins (15, 21,
22), and because they can easily package and integrate ge-
Figure 1. HCV E1E2 and retroviral expression constructs. (A) A
cDNA derived from the HCV polyprotein gene was used to express the
E1E2 glycoproteins and the COOH terminus of the C protein, which
provides the signal peptide for E1 (SP E1). The position of stop codons
(asterisk) inserted in the expression constructs to terminate translation of
the proteins is shown. The transmembrane domain (TMD) of E1 pro-
vides the signal peptide (SP E2) for the E2 glycoprotein (46). NTR, non-
translated region; IRES, internal ribosome entry site. (B) The expression
constructs encoding the different components required to assemble infec-
tious pseudo-particles are shown. The shaded boxes represent the viral
genes and the marker gene (GFP) transferred to the infected cells. The
open boxes show the cis-acting sequences. LTR, long terminal repeat;
CMV, cytomegalovirus immediate-early promoter; PBS, primer binding
site; 	, packaging sequence; PPT, poly-purine track; polyA, polyadenyl-
ation site. Vector particles were produced by cotransfection of plasmids
harboring the packaging functions, the transfer vector and the viral glyco-
proteins (GP) into 293T cells. The viral GPs were the HCV E1 and E2
glycoproteins, expressed individually or as a CE1E2 polyprotein (Fig. 1
A), the VSV-G, or the RD114 glycoproteins. The supernatants of trans-
fected cells were collected during transient expression, concentrated by
ultracentrifugation, and used for target cell transduction.
Figure 2. Assembly of HCV pseudo-particles. (A) Detection of E2 glyco-
proteins by flow cytometry. E1E2-transfected 293T cells were or were not
permeabilized before staining with A4 or H53 monoclonal antibodies against
E1 (28) and E2 (black areas; reference 47). Cell-bound antibodies were incu-
bated with FITC-conjugated antibodies before FACS® analysis. The back-
ground staining was provided by staining the cells with the conjugated anti-
bodies only (white areas). (B) Immunoblots of lysates of 293T-transfected
cells and of pseudo-particles pelleted through 20% sucrose cushions are
shown. Expression of E1 and E2 glycoproteins from HCV-1a genotype and
of MLV core proteins was revealed in reducing and denaturing conditions
with A4 and H52 monoclonal antibodies against E1 (28) and E2 (29) or with
an anticapsid (MLV CA) antiserum. VSV-G expressed in control pseudo-
particles was detected with the monoclonal antibody P5D4. The positions of
the molecular mass markers (kD) are shown. E2 present within the viral pel-
lets migrated slightly slower than the cell-associated forms due to modifica-
tions of the associated glycans by Golgi enzymes (not depicted). The pres-
ence of VSV-G in viral pellets generated with MLV-G2A assembly-defective
core proteins is due to empty vesicles formed by VSV-G itself (48). (C) Im-
munoblots of lysates of 293T producer cells and of purified pseudo-particles
generated with E1 or E2 expressed alone, from two separate expression units,
or coexpressed in trans or in cis, from a CE1E2 polyprotein (E1E2).
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netic markers into DNA of infected cells (23). HCVpp
were produced by transfecting human 293T cells with
three expression vectors (Fig. 1 B) encoding a 
 

 
CE1E2
polyprotein, the MLV Gag-Pol core proteins, and a pack-
aging-competent MLV–derived genome encoding the
green fluorescent protein (GFP) marker protein. Control
pseudo-particles were generated without glycoproteins,
with the VSV-G glycoprotein (11), with the feline endoge-
nous virus RD114 glycoprotein (15), and/or with assem-
bly-defective MLV core proteins (MLV-G2A; reference
24). Analysis of immunoblots of transfected cells showed
that the structural components of the pseudo-particles were
readily detected at the expected molecular masses; i.e., 
 

 
30
kD for E1, 
 

 
60 kD for E2, 
 

 
60 kD for VSV-G (Fig. 2, B
and C), and 
 

 
70 kD for the RD114 glycoprotein (unpub-
lished data). MLV core proteins were detected as Gag pre-
cursors of 65 kD that were partially processed by the MLV
protease into mature core components (Fig. 2 B). Viral par-
ticles were harvested from the supernatant of transfected
cells and purified by ultracentrifugation through high den-
sity sucrose cushions, a purification process that removes
loosely associated glycoproteins (25, 26). The E1 and E2
glycoproteins were readily detected in the pellets of puri-
fied virions generated with the wild-type MLV core parti-
cles but not with the viral assembly-deficient MLV-G2A
mutant (Fig. 2 B). Comparison of the relative levels of
VSV-G or HCV glycoproteins in producer cell lysates ver-
sus viral pellets suggested efficient incorporation of E1 and
E2 into viral particles. Likewise, E1 and E2 glycoproteins
could efficiently assemble on retroviral core proteins de-
rived from HIV-1 (unpublished data), raising the possibility
of pathogenic interactions between the two parental viruses
in vivo because coinfection of patients with HCV and HIV
is prevalent (2). Further evidence that the E1 and E2 glyco-
proteins were properly incorporated on retroviral core par-
ticles was provided by their analysis on density gradients
(unpublished data). Immunoblots of viral particles fraction-
ated through an equilibrium density centrifugation in 20–
60% sucrose gradients indicated that the same fractions
contained the Gag-Pol core proteins and the envelope gly-
coproteins, for both HCVpp and control pseudo-particles,
at a sucrose density that corresponded to that of bona fide
retroviral particles. Altogether, these results indicated that
transient expression of E1 and E2 in 293T cells leads to
specific and efficient incorporation of HCV glycoproteins
into pseudo-particles generated with retroviral cores. Al-
though HCV envelope glycoproteins have been shown to
be retained in the ER in several cell types (19), our FACS
 
®
 
results of transfected 293T cells show that a small fraction
of E1 and E2 reach the cell surface (Fig. 2 A), where MLV
budding normally occurs (24), most likely due to satura-
tion/leakiness of the ER retention on overexpression.
Therefore, our data suggest that HCVpp may bud from the
cell surface and not from the ER lumen.
To further investigate the role of HCV glycoproteins in
incorporation on retroviral cores, we designed expression
vectors that encoded individually either E1 or E2 glyco-
proteins (Fig. 1 A). Individual expression or coexpression
of E1 and E2 from distinct expression units in trans led to
normal levels of synthesis, as compared with expression of
both glycoproteins in cis from a single E1E2 polyprotein
(Fig. 2 C). Moreover, HCVpp were found to incorporate
similar levels of E2 glycoprotein, whether it was expressed
alone, or coexpressed with E1 in cis or in trans (Fig. 2 C).
Finally, incorporation of E1 expressed alone or coexpressed
in trans, with E2, occurred but at reduced levels, consistent
with the chaperone activity of the latter protein (19).
 
HCV Pseudo-particles Infect Hepatic Cells. 
 
We assessed
the infectivity of HCVpp on a panel of target cell lines.
Cells were incubated for 3 h with dilutions of supernatants
containing the HCVpp, washed, and cultured until expres-
sion of the GFP marker gene harbored by the virions was
measured by FACS
 
®
 
 analysis 72 h later. Because HCVpp
were generated with replication-defective viral compo-
nents, this procedure allowed evaluation of the specific in-
fectivity of the pseudo-particles after a one-round infection
process. The capsid–protein content of HCVpp and con-
trol pseudo-particles generated with VSV-G was identical
for virions prepared simultaneously (Fig. 2, B and C), al-
lowing direct comparison of their respective infectivity.
However, consistent with previous studies comparing
batches of pseudo-particles prepared independently (15),
we found important variations in capsid amounts (unpub-
lished data) despite similar infectious titers (Fig. 3 A). Thus,
to minimize artifacts due to differences in the quality of
HCVpp stocks, infectivity was defined as TU per milliliter
rather than TU per nanogram of capsid proteins. Infectious
titers of up to 3 
 

 
 10
 
5
 
 TU/ml (mean, 1.7 
 

 
 10
 
5
 
 
 


 
 10
 
5
 
;
 
n
 
 
 

 
 6) were reproducibly obtained for the HCVpp on
Huh-7 human hepato-carcinoma cells (Fig. 3 A). Upon con-
centration of the producer cell supernatants by ultracentrif-
ugation, infectious titers of 2 
 

 
 10
 
6
 
 TU/ml, on average,
could be readily obtained (Fig. 3 A). The other target cell
types used in the infection assays displayed weaker (PLC/
PRF/5, Hep 3B, HepG2, Caco-2, HT1080, HT-29,
LoVo, MCF-7, U118, 293T, and Vero) or undetectable
(A431, HCT 116, HOS, TE671, Jurkat, Molt-4, CEM,
Raji, CMMT, Cos-7, BHK-21, CHO, PG-4, BRL 3A,
NIH/3T3, and QT6) levels of infection with the HCVpp
(Fig. 3 A), although all these cells were readily infected
with control pseudo-particles generated with VSV-G and
with titers over 7 
 

 
 10
 
6
 
 TU/ml (unpublished data). This
suggested that all the molecules necessary for HCV entry
were sufficiently expressed in the former cell types. Infec-
tious HCVpp could be generated at comparable efficiencies
with E1E2 glycoproteins derived from HCV genotypes 1a
and 1b (Fig. 3 B, h and i) and/or with retroviral core pro-
teins derived from either HIV-1 or MLV (Fig. 3 B, d and
h). Incubation of HCVpp and target cells with AZT, a re-
verse-transcriptase inhibitor that prevents conversion of the
retroviral RNA genome of the HCVpp into integration-
competent proviral DNA, inhibited transduction (Fig. 3 B,
j). Moreover, long-term expression of GFP could be dem-
onstrated after serial passaging of infected cells for more
than one month (unpublished data). These results indicated
that infection of the target cells led to integration into the
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host cell DNA and stable expression of the GFP marker
gene transduced by the HCVpp. Additionally, no infection
could be obtained with viral particles lacking both E1 and
E2 glycoproteins, or lacking core proteins, or, alternatively,
when using the MLV-G2A assembly-defective core pro-
teins (Fig. 3 B, a–c). Altogether, these results demonstrate
that HCVpp harboring the E1 and E2 glycoproteins and
retroviral core proteins were infectious, leading to retrovi-
ral-mediated integration of their vector genome. Finally,
despite reduced levels of E1 incorporation (Fig. 2 C),
HCVpp generated with E1 and E2 glycoproteins expressed
in trans, from distinct vectors, were nearly as infectious as
those generated with the E1E2 polyprotein construct (Fig.
3 B, g and h). However, HCVpp assembled with either E1
or E2 glycoproteins only were 500-fold less infectious (Fig.
3 B, e and f), demonstrating that both glycoproteins need
to be coincorporated on HCVpp to allow efficient virus
entry and infection.
Hepatocytes represent the principal site of HCV replica-
tion in vivo, yet ex vivo studies have suggested that HCV
may also infect lymphoid cells (3, 17). To address whether
either cell types could be infected, we transduced human
adult hepatocytes from biopsy samples and PBMCs from
healthy blood donors. Because vectors derived from MLVs
do not efficiently transduce these cells (14, 27), we took ad-
vantage of the possibility that HCVpp can be generated
with HIV-1–derived vectors (Fig. 3 B) that allow efficient
transduction of nondividing target cells (13–15, 27). Rela-
tive to infection of Huh-7 cells, these HCVpp could readily
infect the primary hepatocytes derived from different do-
nors (Fig. 4, A and B), yet the transduction efficiencies
were negatively influenced by the quality and cell culture
viability of the individual biopsies. In contrast, infection of
PBMCs yielded undetectable levels of transduction with
the HCVpp, although control pseudo-particles generated
with VSV-G could readily infect these primary cells (un-
published data), as shown previously (14, 15). Altogether,
these data suggested that HCVpp seem to reproduce the
tropism of infection of wild-type HCV and preferentially
infect hepatocytes and hepato-carcinoma cells.
 
HCV Pseudo-particles Are Neutralized by Antibodies and Pa-
tient Sera. 
 
We sought to determine whether E1 and E2
and their interactions with cell-surface receptors specifically
mediate infectivity of the HCVpp. We used a panel of
monoclonal antibodies shown previously to specifically re-
act against HCV-1a glycoproteins (9, 28–31). About half of
these antibodies significantly inhibited (i.e., 
 

 
20% inhibi-
tion) the infectivity of HCVpp. The H35 and H48 mono-
clonal antibodies, which recognize conformational epitopes
on E2, reduced the infectivity of HCVpp of genotype 1a
by up to 70% (Fig. 5 A). That neutralization was incom-
plete might be due to the fact that these monoclonal anti-
bodies, which were developed and selected for binding to
intracellular E1–E2 complexes, have been shown to be
sensitive to post-translational modifications of E2 (30). In-
deed, we found that, compared with its intracellular coun-
terpart, E2 associated to HCVpp had undergone sugar
modifications (Fig. 2, B and C), most likely as a result of its
export through the cell secretory pathway (Fig. 2 A). Inter-
estingly, none of these genotype 1a-specific antibodies
could neutralize the HCVpp of genotype 1b (unpublished
data) or the VSV-Gpp control pseudo-particles generated
with VSV-G (Fig. 5 A). This indicated that infectivity of
the HCVpp was specifically mediated by E1 and E2 glyco-
proteins and suggested that these pseudo-particles represent
a valid model to investigate the early steps of HCV infec-
tion, i.e., receptor binding, membrane fusion, and enve-
lope uncoating, as well as sero-neutralization.
Next, we investigated whether the infectivity of HCVpp
could be neutralized by sera derived from chronically
HCV-infected patients. HCVpp were incubated with sera
before performing infection assays using Huh-7 as target
Figure 3. Infectivity of HCV pseudo-particles. (A) The results of ex-
periments performed with different target cell types are displayed as TU
per milliliter of supernatant (mean 
 SD of up to six experiments) for
HCVpp of 1a genotype. The infectivity on Huh-7 cells of HCVpp con-
centrated 100 by ultracentrifugation is shown. Similar results of infectiv-
ity and host-range were obtained for HCVpp of 1b genotype (not de-
picted). The infectivity of control pseudo-particles generated with VSV-G
ranged from 7  106 to 2  107 TU/ml, depending on the target cell type
(not depicted). (B) Infectivity of HCV pseudo-particles generated without
E1E2 (a), without retroviral core proteins (b), with MLV-G2A assembly
defective core proteins (c), with HIV-1 core proteins (d), with E1 or E2
alone (e or f, respectively), with E1  E2 expressed in trans from two in-
dependents vectors (g), with HCV-1a E1E2 expressed from the same vec-
tor in cis (h), or with HCV-1b E1E2 (i). HCVpp were treated with 25
µM AZT (3-azido-3-deoxythymidine) before and during infection of
target cells (j). Infectious titers (TU/ml) were determined on Huh-7 target
cells and are displayed as mean 
 SD of up to four experiments.
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cells (Fig. 5 B). No or nonsignificant neutralization of con-
trol pseudo-particles could be detected with patient sera or
with control sera derived from healthy donors. However,
most, if not all, of the patient sera could neutralize the in-
fectivity of HCVpp in contrast to sera derived from healthy
donors (Fig. 5 B). Neutralization levels varied between the
different patient sera from 20
 
 
 
to
 
 
 
90% inhibition of infec-
tion. Interestingly, at a 1:50 dilution, sera derived from pa-
tients infected with genotype 1b neutralized HCVpp-1a
and -1b with similar efficiency, suggesting that cross-neu-
tralization occurs (Fig. 5 B).
 
LDLr and CD81 Are Not the Major Cell Entry Receptors of
HCV Pseudo-particles. 
 
Both the LDL receptor (LDLr)
and CD81, a member of the tetraspanin family of receptors,
have been proposed as putative HCV receptors (32–34).
However, recent studies have questioned the role of these
molecules in HCV cell entry, despite their unequivocal ca-
pacity to bind HCV particles and/or glycoproteins (35–40).
Thus, we sought to investigate the contribution of either
cell-surface molecule in the early stages of HCV cell entry
by performing receptor competition assays. LDLr binds
apolipoprotein B within LDL and apolipoproteins B and E
(ApoB and ApoE) within very low density lipoprotein
(VLDL) complexes; both complexes have been found asso-
ciated with HCV particles in the plasma of infected patients
(36). Purified LDLs and VLDLs were not found to signifi-
cantly out-compete infection of HCVpp on Huh-7 LDLr-
positive cells (Fig. 6 A). When monoclonal antibodies tar-
geted to the receptor binding sites of ApoB and ApoE were
preincubated with the HCVpp and control pseudo-parti-
cles, only the anti-ApoE antibodies could inhibit, albeit
weakly, the infectivity of the HCVpp of genotypes 1a (Fig.
6 A) and 1b (unpublished data). This is consistent with our
observation that HCVpp could not or hardly infect LDLr-
positive cell lines such as HepG2, Jurkat, CEM, Molt-4,
Figure 5. Neutralization of HCV pseudo-particles. (A) Results of neu-
tralization of HCVpp-1a generated with HCV-1a E1E2 and with MLV
core proteins preincubated before infection of Huh-7 cells with 20 µg/ml
saturating concentrations of monoclonal antibodies against E1 (A4) or E2
(H31, H33, H35, H44, H48, H53, H54, H60, and H61) glycoproteins of
genotype 1a. Hmix: neutralization assays with pooled antibodies. Nega-
tive control experiments were performed using no antibodies (Control)
or using pseudo-particles generated with VSV-G (VSV-Gpp). Neutraliza-
tion of the infectivity of these control pseudo-particles was achieved by
using the VSV-G neutralizing 41A.1 monoclonal antibody. Results are
expressed as the percentages of inhibition of the average infectious ti-
ters 
 SD relative to incubation in the absence of antibodies. (B) Results
of neutralization of HCVpp with HCV patient sera. HCVpp of genotypes
1a or 1b were preincubated for 30 min at room temperature with sera
from chronically HCV-infected patients diluted 1:50 before infection of
Huh-7 target cells. The genotype of HCV diagnosed in these patients is
indicated in brackets. Results are expressed as percentages of inhibition of
the average infectious titers 
 SD relative to incubation with control sera
from healthy individuals. Control experiments were performed using
pseudo-particles generated with RD114 glycoproteins (RD114pp), rather
than with VSV-G, which exhibits sensitivity to human complement (15).
Efficient neutralization of the control pseudo-particles (not depicted) was
demonstrated with a hyper-immune goat serum raised against the RD114
SU glycoprotein.
Figure 4. Results of infection on human primary hepatocytes. Infection
assays were performed with HCV pseudo-particles generated with core
proteins derived from HIV-1 rather than from MLV, which do not permit
transduction of nonproliferating target cells (11). (A) Photographs of hu-
man adult primary hepatocytes infected by HCVpp of genotype 1a carrying
a lacZ marker gene encoding a nuclear-targeted -galactosidase. The cells
were stained 3 d after infection with X-Gal, as described previously (26).
Magnification, 150. The specificity of infection was demonstrated by the
absence of transduction when target cells were infected with HIV-1–derived
pseudo-particles lacking glycoproteins (pp cores) or by the reduced levels of
transduction when target cells were preincubated with 30 µg/ml JS-81
anti-CD81 antibodies before infection (JS-81). (B) Quantitative analysis
of the infectivity of HCVpp on hepatocytes derived from two donors is ex-
pressed as a percentage of infectivity determined on Huh-7 cells.
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Raji, and TE671 (Fig. 3 A). Thus, although these results do
not exclude a role of LDLr in HCV entry, possibly via as-
sociation of LDLs/VLDLs with HCV particles (36), they
suggest that LDLr is not the major receptor of HCVpp en-
try. Yet this assertion should be mitigated because in con-
trast to wild-type HCV (36), our HCV pseudo-particles,
which were generated in nonhepatic cells (Fig. 2), may not
be specifically associated with LDLs and VLDLs.
Recombinant GST-fusion polypeptides encompassing
the large extracellular loop (LEL) of human CD81, which
has been shown to bind HCV E2 (29, 34), were then used
to investigate the role of hCD81 in HCVpp cell entry. The
GST-fusion hCD81-LEL polypeptides, preincubated with
the HCVpp, could specifically precipitate E1–E2 com-
plexes (unpublished data), confirming their capacity to bind
the E2 glycoprotein (29, 34), and were found to neutralize
HCVpp infection on Huh-7 cells, yet with a relatively
poor efficiency (Fig. 6 B). Inhibition ranged from 38 to
54% inhibition of infectivity and appeared to be dose-
dependent. Consistently, preincubation of Huh-7 cells with
JS-81 monoclonal antibody, which blocks binding of re-
combinant E2 to hCD81 (29), was found to inhibit infec-
tivity of HCVpp in both Huh-7 target cells (Fig. 6 B) and
human primary hepatocytes (Fig. 4, A and B). At high anti-
body concentrations (30 µg/ml), over 90% inhibition of in-
fection could be obtained for HCVpp based on genotypes
1a (Fig. 6 B) as well as 1b (unpublished data). However,
several target cells nonpermissive to infection by HCVpp,
like TE671, Jurkat, CEM, Molt-4, and Raji cells (Fig. 3 A)
were found to express high densities of hCD81 (unpub-
lished data), indicating a lack of correlation between CD81
expression and HCVpp infection. Moreover, expression of
hCD81 in nonpermissive NIH/3T3 mouse fibroblasts did
not allow infection with the HCVpp (Fig. 6 C). Alto-
gether, these results indicate that although hCD81 binds
HCV E2 and might play a role in cell surface attachment of
HCV, it is not sufficient by itself to allow HCVpp infec-
tion. Additional interactions between the virions and cell-
surface components are likely necessary to allow HCVpp
entry into cells.
 
Discussion
 
Despite 13 yr of research, no efficient and reliable cell
culture system is available to amplify HCV particles, mak-
ing the study of the virus as well as the design of inhibitors
and vaccines very difficult. Here, we have exploited two
well-documented properties of retroviruses––the capacity
to incorporate foreign glycoproteins (15, 21) and the ca-
pacity to integrate and express marker genes from replica-
tion-incompetent viral particles (23)––to generate a spe-
cific, fast, and reliable in vitro infection assay based on
pseudo-particles displaying unmodified E1 and E2 HCV
glycoproteins. Thus, we describe for the first time the for-
mation of highly infectious HCV pseudo-particles that may
share early cell entry properties with parental HCV.
Our data indicate that the E1 and E2 glycoproteins rep-
resent the envelope glycoproteins of wild-type HCV and
are both required for infection; each glycoprotein is poten-
tially involved in separate steps of cell entry (9, 17). Pro-
duction of HCV virus-like particles in insect cells has al-
ready been reported (7, 39–41). However, these particles
were not secreted and their extraction from intracellular
compartments yielded virus-like particle preparations that
were contaminated with cellular materials. Moreover, al-
though useful to analyze interactions with the cell surface,
they were not infectious and did not permit functional in-
vestigation of the putative HCV receptors in cell entry.
Pseudotyped VSV or influenza virus particles have also
been engineered with chimeric E1 and/or E2 glycopro-
teins, whose transmembrane domains were modified to al-
Figure 6. Cell entry receptor usage by HCV pseudo-particles. (A) Re-
sults of LDL receptor competition assays was performed with 10 µg/ml
purified LDLs and VLDLs or using the monoclonal antibodies 5E11, 4G3
(anti-ApoB), or 1D7 (anti-ApoE) preincubated with the pseudo-particles
before infection at the indicated concentrations (µg/ml) are shown. Mix:
the 5E11, 4G3, and 1B7 antibodies were mixed at the indicated in-
dividual concentrations in the neutralization assays. (B) Results of CD81
receptor competition assays are shown. hCD81-LEL GST-fusion
polypeptides were preincubated with the pseudo-particles before infec-
tion or JS-81 anti-CD81 antibodies were preincubated with the target
cells before infection at the indicated concentrations (µg/ml). Results are
expressed as percentages of inhibition of the infectious titers obtained on
Huh-7 cells relative to titers obtained in the absence of inhibitors. Con-
trol experiments were performed using pseudo-particles generated with
VSV-G (VSV-Gpp). (C) Comparative results of infection obtained on
NIH/3T3, NIH/3T3-hCD81, and Huh-7 cells infected with HCVpp
and with VSV-Gpp. Infectious titers (TU/ml) are displayed as mean 

SD of up to three experiments.
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low transport to and assembly at the cell surface (8–10, 42).
However, such modifications disturb conformation and
functions of the E1–E2 complexes (42), and although VSV
pseudo-particles stand among candidate HCV vaccines
(43), their use as a tool to investigate HCV assembly and
cell entry remains controversial (8). In contrast, we found
that no structural modifications of the E1E2 glycoproteins
were required for their correct assembly on retroviral and
lentiviral cores nor for the generation of high titer infec-
tious HCVpp with functional E1E2 glycoproteins.
Our findings that HCVpp show a preferential tropism
for hepatic cells (Figs. 3 and 4), and that they are specifi-
cally neutralized by anti-E2 monoclonal antibodies as well
as sera of HCV-infected patients (Fig. 5), further support
the contention that the E1–E2 complexes assembled on
HCVpp mimic those displayed by parental HCV. There-
fore, the HCVpp described here may represent a valid
model to investigate some of the infectious properties of
HCV. Although we found evidence that proposed previ-
ously that HCV receptor candidates, LDLr and CD81 (32–
34), may be involved in the early steps of infection, by me-
diating binding of HCV glycoproteins and viral particles (9,
10, 29, 31–40, 42), we show that none of these molecules
were sufficient to permit infection (Fig. 6). Indeed, some
human cells that express LDLr and/or CD81 were found to
be nonpermissive to infection (Fig. 3). Additionally, ec-
topic expression of human CD81 did not restore infection
in nonpermissive murine cells (Fig. 6). One may consider
that these LDLr
 

 
/CD81
 

 
 cells are nonpermissive for
HCVpp infection as a result of expression of a factor that
prevents infection rather than as a result of lack of expres-
sion of a critical HCV receptor component. However, we
favor the latter hypothesis because if a negative factor was
expressed in these cells, it should restrict infection of both
the HCVpp and the control pseudo-particles, for which
the only difference lies in the composition of the viral en-
velope. Indeed, such cells could be readily infected when
the HCV-specific receptor/entry phase of infection was
bypassed by using alternative glycoproteins such as VSV-G
or RD114 Env (Fig. 6 C; unpublished data). These data
suggest that, like many other viruses (44, 45), the different
steps of HCV entry (i.e., binding, internalization, and cell
penetration) are mediated by different molecules. With the
HCVpp described here, it should become possible to inves-
tigate these early events of HCV infection in detail and to
identify novel HCV receptors or coreceptors.
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